Xenleta (lefamulin) is a small molecule pharmaceutical. Lefamulin was first approved as Xenleta on 2019-08-19. It is used to treat bacterial pneumonia in the USA. It has been approved in Europe to treat bacterial pneumonia and community-acquired infections. Xenleta's patents are valid until 2031-05-23 (FDA).
|Indication||bacterial pneumonia, community-acquired infections|
|Drug Class||Antibacterials, pleuromulin derivatives|